ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.87 USD
-0.01 (-0.35%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $2.86 -0.01 (-0.35%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum D VGM
ADC Therapeutics SA (ADCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.00 | $13.00 | $8.00 | 247.22% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for ADC Therapeutics SA comes to $10.00. The forecasts range from a low of $8.00 to a high of $13.00. The average price target represents an increase of 247.22% from the last closing price of $2.88.
Analyst Price Targets (5 )
Broker Rating
ADC Therapeutics SA currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.43 | 1.75 | 1.86 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/30/2024 | Cantor Fitzgerald & Co | Eric Schmidt | Not Available | Strong Buy |
4/4/2024 | Capital One Securities | Naureen Quibria | Strong Buy | Strong Buy |
3/28/2024 | Guggenheim Securities | Michael Schmidt | Not Available | Strong Buy |
3/14/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
3/6/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $10.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 91 of 253 |
Current Quarter EPS Est: | -0.44 |